title: Testicular relapse of AML during chronic graft-versus-host disease induced by donor leukocyte infusion.
abstract: Treatment options for acute leukemia relapsing after allogeneic BMT include conventional chemotherapy or a second transplant; however, results are rather discouraging, the first option being associated with poor survival and the second with a high mortality rate. More recently, donor leukocyte infusion (DLI) from the original donor has been used for relapsed patients in an attempt to induce a graft-versus-leukemia (GVL) effect. This procedure is partially devoid of the toxicity inherent to a second BMT. At our Institution, a 36-year-old patient with biphenotypic AML in second complete remission after relapse following allogeneic BMT was treated with peripheral blood stem cell (PBSC)-enriched donor leukocytes, obtained after in vivo priming with rhG-CSF. The patient experienced extensive cGVHD but developed a testicular relapse while in full hematologic remission. After irradiation of the sanctuary site he remains free of disease, still with chronic GVHD, 21 months after bone marrow relapse. This case suggests that immunologically privileged sites are inaccessible to GVHD/GVL effect. This should be considered when planning salvage transplants procedures in patients at risk for extramedullary involvement.
authors.affiliation: Department of Hematology and Bone Marrow Transplant Unit, Ospedale Cervello, Palermo, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Tringali
authors.forename: S
authors.initials: S
authors.lastname: Vasta
authors.forename: R
authors.initials: R
authors.lastname: Scimè
authors.forename: P
authors.initials: P
authors.lastname: Catania
authors.forename: A M
authors.initials: AM
authors.lastname: Cavallaro
authors.forename: I
authors.initials: I
authors.lastname: Majolino
mesh_terms: D000328:Adult; D006086:Graft vs Host Disease / Q000209:etiology* / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D017708:Leukocyte Transfusion / Q000009:adverse effects*; D008297:Male; D013736:Testicular Neoplasms / Q000556:secondary*